

Correction to: Randomized trial of First-Line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-Mutated Non-Small cell lung cancer

This is a correction to: Xiao-Shan Wang, MD, Yi-Feng Bai, MD, Vivek Verma, MD, Rui-Lian Yu, MD, Wei Tian, MS, Rui Ao, MD, Ying Deng, MD, Xue-Qiang Zhu, MD, Hao Liu, MD, Hai-Xia Pan, MD, Lan Yang, MD, Han-Song Bai, MD, Xing Luo, MD, Yan Guo, MS, Ming-Xiu Zhou, MD, Yue-Mei Sun, MD, Zi-Can Zhang, MD, Si-Min Li, MD, Xue Cheng, MD, Bang-Xian Tan, MD, Liang-Fu Han, MD, Ying-Yi Liu, MD, Kai Zhang, MD, Fan-Xin Zeng, PD, Lin Jia, MD, Xin-Bao Hao, MD, You-Yu Wang, MD, Gang Feng, MD, Ke Xie, MD, You Lu, MD, Ming Zeng, MD, PhD, Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer, *JNCI: Journal of the National Cancer Institute*, 2022; djac015, <https://doi.org/10.1093/jnci/djac015>

Following article publication, Jian-Ling Xia, M.D., and Yang-Ke He, M.D., contacted the journal, stating they do not meet the journal's authorship criteria and requesting to be removed as co-authors. They have since been removed from the author byline, as well as the Author Contributions section, in the latest version of the article. A note has also been added to the Acknowledgements section, stating the Journal has been unable to reach Bang-Xian Tan, M.D., to confirm their authorship, but the co-authors attest to Dr. Tan's contributions to the manuscript and affirm they meet the Journal's criteria for authorship.